Evommune and Maruho Expand their Partnership for the Development and Commercialization of EVO756 in Greater China and Asian Countries
Shots:
- Evommune and Maruho have signed an expanded strategic collaboration for the development & commercialization of EVO756 across Greater China & Asian regions under which the former will obtain up front & milestone payments of $62M
- The company is conducting SAD and MAD P-I study to assess the safety, tolerability & PK/PD of EVO756 (oral) on mast cell degranulation via a skin challenge test among healthy adults & chronic spontaneous urticaria (CSU) patients
- EVO756 is a potent, highly selective small molecule MRGPRX2 antagonist indicated for multiple inflammatory conditions and having a potential for treating a variety of mast cell mediated diseases
Ref: Evommune | Image: Evommune
Related News:- Evommune Collaborated with Maruho to Develop and Commercialize EVO756 in Japan
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
